Markets in the Middle East and North Africa (MENA) offer opportunities for growth for the pharmaceutical industry, but the landscape is changing. Not least, the region is expressing more interest in the use of health technology appraisals (HTAs) to inform pricing and formulary decisions, while some countries are considering managed entry agreements.
The Middle East and North Africa region will represent a $64bn opportunity for pharmaceutical companies by 2021, according to Ayman Semaan, market access manager at